Clinical Trials Browser

Goserelin × Head & Neck × 90 days × Clear all

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms